Pricing Log in Create free account
Saturday 17 October 2026 Export IDXX’s income statement to Excel — free account

IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%
Market cap
$43.1B
P/E
39.1×
Fwd P/E
38.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

IDEXX Laboratories, Inc. 10-K filed Feb 20, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:09 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 21, 2025: 2 added · 6 removed · 68 modified

  1. Modified · COMPANY OVERVIEW

    IDEXX was incorporated in Delaware in 1983. We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary,; livestock and , poultry, and dairy; and water testing industries. We also provide manufacture and sell human medical point-of-care and laboratory diagnosticsdiagnostic products. Our primary products and services are:

75 more changes in this Item, word by word, in Powerpack.

Powerpack